Navigation Links
Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
Date:8/14/2013

GREENWOOD VILLAGE, Colo., Aug. 14, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced positive results from the SPRING study (clinicaltrials.gov NCT01839331) of Ampion for the treatment of osteoarthritis of the knee (OAK). In this study of 329 patients, patients treated with a single intra-articular injection of Ampion achieved a clinically meaningful reduction in pain.

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

The SPRING study, was a randomized (1:1:1:1), double-blind, vehicle controlled trial designed to evaluate the safety and efficacy of Ampion in OAK patients. Patients were randomized to receive one of two doses (4 mL or 10 mL) of Ampion or corresponding saline control via intra-articular injection. The primary study objective was to evaluate the relative efficacy of Ampion 4 mL versus Ampion 10 mL. The primary endpoint was mean change in pain from baseline for Ampion compared to the same volume of saline. Secondary endpoints included evaluating safety and quality of life, as well as, stiffness and function.

Ampion dose cohorts experienced statistically significant reductions in pain compared to control. There were no significant differences between the efficacy of the two Ampion doses. Selection of the optimal dose for the second Phase 3 trial will be decided in consultation with the U.S. Food and Drug Administration (FDA). 

Michael Macaluso, Chairman and Chief Executive Officer, said, "We are very pleased with the results of the trial. Both doses of Ampion provided osteoarthritis patients with pain relief. The broad inclusion criteria for the trial reflected a real world application of this biologic to a diverse patient population, making these results even more impressive. This should greatly encourage the enormous population of patients afflicted w
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Ampio Pharmaceuticals Schedules 2012 Update Webcast
4. Four-Time Triathlon World Champion Melanie McQuaid Selects Polar USA as Official Heart Rate Training Solution
5. Ampios CEO and CSO Send Message to Shareholders
6. Ampio Pharmaceuticals Announces Proposed Public Offering
7. Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,615,400 Shares of Common Stock
8. Ampio Pharmaceuticals Announces Exercise of Over-Allotment Option
9. Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China
10. Ampio Pharmaceuticals Announces Closing of Public Offering
11. eCardio Supports the Carolinas HealthCare Foundation Through Grant for Heart Of A Champion Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 About Neuroendovascular Coil ... to treat an unruptured and ruptured brain aneurysm ... treatment is either known as an endovascular coiling ... coil blocks the blood flow in an aneurysm. ... general anaesthesia by an interventional neuroradiologist using fluoroscopic ...
(Date:9/2/2015)... , Sept. 2, 2015 About Chronic ... a malignant condition characterized by increased production of lymphocytes. ... B-lymphocytes and then it can spread to other parts ... later stages because of the slow buildup of the ... malignancy spreads to the spleen, liver, and lymph nodes. ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... the "Inhaled Drug Delivery (London, UK - November ... This Inhaled Drug Delivery meeting will cover industry case ... much more. The Co-Chairmen are Dr Steven Nichols ... Senior Director, Mylan. Companies participating include: ...
Breaking Medicine Technology:Global Neuroendovascular Coil Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3
... May 12 /PRNewswire-Asia-FirstCall/ -- China Biologic,Products, Inc. (Nasdaq: CBPO ... China , today announced that its,majority-owned subsidiary, Shandong Taibang Biological ... Health,Department to build two new plasma stations. , ... "This approval ...
... , COLUMBUS, Ohio , May 11 Mettler-Toledo International Inc. ... the Baird Growth Stock Conference in Chicago on Tuesday, May ... Eastern Time ).  To hear a live webcast of the presentation, visit the ... replay of the webcast will be available for seven days. , ...
Cached Medicine Technology:China Biologic Products to Build Two New Plasma Stations in Shandong Province 2China Biologic Products to Build Two New Plasma Stations in Shandong Province 3China Biologic Products to Build Two New Plasma Stations in Shandong Province 4Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Growth Stock Conference 2
(Date:9/2/2015)... ... September 03, 2015 , ... ... determine who among America’s policymakers, public servants, activists, corporate executives, entrepreneurs, health care ... care. This year, that process led the magazine to tap the National League ...
(Date:9/2/2015)... ... September 02, 2015 , ... On ... Officers Association of America (MOAA) and Wounded Warrior Project® (WWP), will be ... Own,” expert panelists will lead interactive discussions on the responsibilities and commitments ...
(Date:9/2/2015)... CA (PRWEB) , ... September 02, 2015 , ... Based ... expand their fleet of truly superb luxury vehicles based on which of the latest ... to announce the latest step forward in pursuit of this goal: a 2015 ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... – in the news recently following a decision by the Centers for Medicare ... is likely to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... safety and efficacy endpoint data collection, cloud analytics and workflow solutions today ... The series enables pharmaceutical researchers to participate in interactive programs in which ...
Breaking Medicine News(10 mins):Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3
... who self-paid for their antiretroviral medications experienced interruptions ... or supply logistical disruptions. These treatment interruptions led ... in patients. ,These findings by a ... Institute at Makerere University, Kampala, and UCSF are ...
... 135-2 to pass (HB 1098) a Senate-approved bill that would ... until 2011, the New York Times reports.// ,Gov. ... that mandates that all girls entering the sixth grade beginning ... the executive order will allow parents who do not want ...
... least 3 years after undergoing in vitro fertilization (IVF) ... cell// research, according to a report. ,The ... of the report, was the complete and clear explanation ... legal advisor and embryologist, which helped couples navigate the ...
... Institute is seeking to raise glaucoma awareness among Mexican-Americans,// who ... Casa Grande Valley Dispatch reports. ,Mexican-Americans over ... family history of glaucoma all face a higher risk for ... the most common form glaucoma. ,The rate ...
... music and witty tales kept Delhi audiences enthralled as spiritual ... happiness and peace. ,Far from being a moral ... Thursday on 'Circus of the mind' was a simple talk ... is a very well-coordinated activity made to look like a ...
... The amount Americans spent on arthritis medications more than ... number of people// with the disease, increases in the ... inflation-adjusted cost per prescription, according to a new study ... a six-year study of U.S. arthritis patients and the ...
Cached Medicine News:Health News:Resistance to Anti-HIV Drugs in Uganda Developed Due to Drug Supply Problems 2Health News:Many Couples Choose to Donate Surplus Embryos for Stem Cell Research 2Health News:Mind Control is the Key to Happiness: Sadguru Jaggi Vasudev 2Health News:Treatment Cost for Arthritis on the Rise: Study 2
... Used to dilate the ... medium to assess possible submucosal ... a topical anesthetic in the ... passage by, or dislodgment of ...
Used for drainage and retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for drainage and navigation of a tortuous ureter. The tapered tip eases placement as there are no edges to interfere with the ureteral orifice. Supplied sterile in peel-open packages. Intended f...
... constructed of stainless steel Delta Wire. The ... a three-prong grasper with the largest possible ... Delta Wire creates a grasper with increased ... in the ureter. Supplied sterile in peel-open ...
Medicine Products: